Navigation Links
Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
Date:2/17/2009

PRINCETON, N.J., Feb. 17 /PRNewswire-FirstCall/ -- Novo Nordisk, a global healthcare company focusing on diabetes care, today announced the appointment of Andy Ajello as vice president for National Diabetes Sales, Managed Care and Government Accounts. Ajello joins the Executive Team and will report directly to Jerzy Gruhn, president of Novo Nordisk's North American affiliate.

Ajello was most recently the associate vice president of Diabetes Sales for the eastern area, where he led more than 600. In his new position, he will lead the company's 2,000-person field sales organization. Ajello joined Novo Nordisk in 2001 where he helped to launch NovoLog(R) (insulin aspart [rDNA origin] injection).

"In his eight years at Novo Nordisk, Andy has developed an impressive track record for building high performing field sales teams," said Jerzy Gruhn, president of Novo Nordisk Inc. "His focus on cross-functional collaboration, quick decision-making and strategic execution will help us continue our growth and ultimately realize our ambition of changing diabetes."

Ajello has been recognized and awarded at Novo Nordisk for achievements in sales leadership, training, and marketing, including being named as the Novo Nordisk International Sales Manager of the Year in 2007. Ajello's unique style and insights into team development and management were featured in a Wall Street Journal article in 2008. Prior to Novo Nordisk, Ajello held a 10-year tenure at GlaxoSmithKline.

Ajello received a Bachelor's degree in economics from Susquehanna University.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit novonordisk-us.com.


'/>"/>
SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Appoints New Leader of North American Business
2. Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
3. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
4. Novo Nordisk Increased Net Profit by 32% in 2007
5. Novo Nordisk Files Annual Report with the SEC
6. Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
7. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
8. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
9. Novo Nordisk Makes its Debut in FORTUNEs 100 Best Companies to Work For
10. WorldHeart Appoints David Pellone Chief Financial Officer
11. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Pa. , Oct. 12, 2017 ... leader in innovative solutions for injectable drug administration, today ... before the market opens on Thursday, October 26, 2017, ... the results and business expectations at 9:00 a.m. Eastern ... (U.S.) or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology: